Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Cash from Financing Activities of -$776000.0 for Q1 2026, down 21.25% sequentially from -$640000.0 in Q4 2025, and up 41.39% YoY from -$548837.6 in Q1 2025.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Cash from Financing Activities for 15 years, with the latest figure at -$776000.0 in Q1 2026.
- Quarterly Cash from Financing Activities rose 41.39% year-over-year to -$776000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$2.4 million (down 59.43% YoY) and the FY2025 annual result came in at -$2.9 million, down 1774.84% from the prior year.
- Cash from Financing Activities eased to -$776000.0 in Q1 2026 per VNDA's latest filing, from -$640000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $605000.0 in Q4 2022 and troughed at -$1.3 million in Q1 2025.
- A 4-year average of -$344777.8 and a median of -$425000.0 in 2025 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities slumped 312.9% in 2025, then jumped 41.39% in 2026.
- Over 4 years, Cash from Financing Activities stood at $605000.0 in 2022, then tumbled by 125.62% to -$155000.0 in 2024, then plunged by 312.9% to -$640000.0 in 2025, then decreased by 21.25% to -$776000.0 in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$776000.0, -$640000.0, and -$517000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -856,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -856,000.00 |
| Mar 31, 2026 | -776,000.00 |
| Dec 31, 2025 | -640,000.00 |
| Sep 30, 2025 | -517,000.00 |
| Jun 30, 2025 | -425,000.00 |
| Mar 31, 2025 | -1.32 Mn |
| Dec 31, 2024 | -155,000.00 |
| Dec 31, 2022 | 605,000.00 |
| Sep 30, 2022 | 4,000.00 |
| Jun 30, 2022 | 125,000.00 |
| Dec 31, 2021 | 1.04 Mn |
| Sep 30, 2021 | 371,000.00 |
| Jun 30, 2021 | 289,000.00 |
| Mar 31, 2021 | 1.85 Mn |
| Dec 31, 2020 | 1.43 Mn |
| Sep 30, 2020 | 123,000.00 |
| Jun 30, 2020 | 3.60 Mn |
| Mar 31, 2020 | 479,000.00 |
| Dec 31, 2019 | 2.12 Mn |
| Sep 30, 2019 | 558,000.00 |